当前位置:首页 > 报告详情

1210_Secemsky.pdf

上传人: 明**** 编号:1012201 2025-12-21 22页 972.39KB

1、Eric A.Secemsky,MD,MSc,RPVI,FACC,FAHA,FSCAI,FSVM Director|Vascular Intervention|Beth Israel Deaconess Medical CenterSection Head|Interventional Cardiology and Vascular Research|Richard A.and Susan F.Smith Center for Outcomes Research Associate Professor of Medicine|Harvard Medical SchoolWHATS ON THE

2、 HORIZON FOR THE CALCIFIED FEM-POP SEGMENT?NYEVS 20252Funding:NIH/NHLBI K23HL150290,Food&Drug AdministrationGrants to Institution:Abbott/CSI,BD,Boston Scientific,Cook,Medtronic,PhilipsSpeaking/Consulting:Abbott/CSI,BD,BMS,Boston Scientific,Cagent,Conavi,Concept Medical,Cook,Cordis,Endovascular Engin

3、eering,Gore,InfraRedx,Medtronic,Philips,RapidAI,Rampart,R3,Shockwave,Teleflex,Terumo,Thrombolex,VentureMed and ZollDisclosures31.Katsanos,K.,et al.Debulking Atherectomy in the Peripheral Arteries:Is There a Role and What is the Evidence?Cardiovasc Intervent Radiol.2017;40:964977.2.TurboHawk Peripher

4、al Plaque Excision System U.S.Indications.https:/ Challenges Associated with Problematic CalciumSPL75289 REV A Peripheral IVL Speaker Deck Many challenges exist when treating problematic calcium and complications can ariseTechnologies used to modify calcium have limitations both in mechanism of acti

5、on and safety profile,including a risk of distalembolization and increased procedure time.In addition,they are contraindicated following subintimal lesion crossing,1and are not specifically indicated forintervention in the iliacs.2An opportunity exists for a technology to address these gaps.Emboliza

6、tionPerforationsDissectionsStent CrushAccess for Large-Bore DevicesVessel Recoil41.https:/ E8,L6 and M5+catheters Instructions for Use and Tech sheets.3.https:/ on File at Boston Scientific.Shockwave Peripheral IVL1-3(Johnson&Johnson MedTech)SEISMIQTMIntravascular Lithotripsy System4(Boston Scientif

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据《Data》标记内容,全文主要围绕以下关键点: 1. **研究背景**:治疗问题钙化存在挑战,包括技术局限性、并发症风险和手术时间增加。 2. **技术介绍**:SEISMIQTM Intravascular Lithotripsy System(SEISMIQ IVL)通过激光能量转化为声压波来破碎钙化。 3. **临床研究**: - RESTORE ATK:95名患者,94%严重钙化,30天无主要不良事件(MAE)。 - RESTORE BTK:20名患者,30天无MAE,47.5%直径狭窄急性减少。 4. **产品特点**:SEISMIQ IVL提供高效治疗、延长治疗区域、多尺寸选择和易于使用的特点。 5. **应用前景**:SEISMIQ IVL在治疗下肢血管钙化病变方面具有广阔的应用前景。
新技术的突破" 革新血管治疗" 钙化难题的解决方案"
客服
商务合作
小程序
服务号
折叠